Health Trials

Relapsed B-Cell Non-Hodgkin Lymphoma

3

Review clinical trials related to Relapsed B-Cell Non-Hodgkin Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ImmunityBio, Inc.Updated: May 4, 2026Locations: 2
Eligibility criteria

Have completed ≥2 lines of cytotoxic chemotherapy. [+2]

Histologically documented primary CNS lymphoma, CLL, Burkitt, Burkitt-like lymph... [+25]

Read more
Status: Not yet recruiting

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Open-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: ImmunityBio, Inc.Updated: Mar 17, 2026
Eligibility criteria

Age ≥ 18 to ≤ 75 years old. [+8]

Histologically documented large B-cell lymphomas (eg, diffuse large B-cell lymph... [+24]

Read more
Status: Recruiting

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.

Participants needed: 42
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Mar 25, 2025Locations: 3
Eligibility criteria

Subjects voluntarily participate in clinical research; [+7]

Prior antitumor therapy with insufficient washout period. [+7]

Read more